Replimune, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $682.5M

Website

Clinical Trials

An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma

Conditions: Advanced Melanoma

First Posted Date: 2024-09-11

Last Posted Date: 2024-09-11

Lead Sponsor: Replimune Inc.

Registration Number: NCT06590480

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Phase 2

Recruiting

Conditions: Metastatic Uveal Melanoma

Interventions: Biological: RP2
Biological: Ipilimumab
Biological: Nivolumab

First Posted Date: 2024-09-03

Last Posted Date: 2024-11-20

Lead Sponsor: Replimune Inc.

Target Recruit Count: 280

Registration Number: NCT06581406

Locations: 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸
HonorHealth Research Insisute, Scottsdale, Arizona, United States
🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)

Phase 3

Recruiting

Conditions: Advanced Melanoma

Interventions: Biological: Vusolimogene Oderparepvec
Biological: Nivolumab + Relatlimab
Biological: Nivolumab
Biological: Pembrolizumab
Drug: Single-agent chemotherapy

First Posted Date: 2024-02-16

Last Posted Date: 2024-11-20

Lead Sponsor: Replimune Inc.

Target Recruit Count: 400

Registration Number: NCT06264180

Locations: 🇺🇸
Stony Brook University Cancer Center, Stony Brook, New York, United States
🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 11 locations

Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Phase 2

Withdrawn

Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma
Squamous Cell Carcinoma of Head and Neck

Interventions: Biological: RP3
Other: CCRT(concurrent chemoradiation therapy)
Other: carboplatin and paclitaxel
Biological: nivolumab

First Posted Date: 2023-02-24

Last Posted Date: 2023-12-29

Lead Sponsor: Replimune Inc.

Registration Number: NCT05743270

Locations: 🇨🇿
Fakultni Thomayerova Nemocnice, Prague, Czechia
🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇫🇷
CHU Nimes, Instiut de Cancerologie du Gard, Medical Oncology, Nîmes, France

and more 31 locations

RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Biological: RP2
Biological: Bevacizumab
Biological: Atezolizumab

First Posted Date: 2023-02-17

Last Posted Date: 2024-11-20

Lead Sponsor: Replimune Inc.

Target Recruit Count: 60

Registration Number: NCT05733598

Locations: 🇺🇸
University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

and more 1 locations

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Phase 2

Active, not recruiting

Conditions: MSS
Refractory Metastatic Colorectal Cancer
pMMR

Interventions: Biological: RP2
Biological: RP3
Biological: atezolizumab
Biological: bevacizumab

First Posted Date: 2023-02-17

Last Posted Date: 2024-04-02

Lead Sponsor: Replimune Inc.

Target Recruit Count: 4

Registration Number: NCT05733611

Locations: 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of Washington Seattle Cancer Care Alliance, Seattle, Washington, United States

Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumor

Interventions: Biological: RP3
Biological: Nivolumab

First Posted Date: 2021-02-03

Last Posted Date: 2024-08-09

Lead Sponsor: Replimune Inc.

Target Recruit Count: 123

Registration Number: NCT04735978

Locations: 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇫🇷
Laboratoire de Recherche Translationnelle en Immunotherapie (LRTI), Gustave Roussy, Villejuif, France

and more 10 locations

A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies

Phase 1

Recruiting

Conditions: Melanoma
Cutaneous Squamous Cell Carcinoma
Basal Cell Carcinoma
Merkel Cell Carcinoma

Interventions: Biological: RP1, intra-tumoral injection, oncolytic virus

First Posted Date: 2020-04-16

Last Posted Date: 2024-10-08

Lead Sponsor: Replimune Inc.

Target Recruit Count: 65

Registration Number: NCT04349436

Locations: 🇺🇸
Medical Dermatology Specialists, Phoenix, Arizona, United States
🇺🇸
University of California, San Diego, La Jolla, California, United States
🇺🇸
University of California, Los Angeles, Los Angeles, California, United States

and more 15 locations

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

Phase 1

Recruiting

Conditions: Cancer

Interventions: Biological: RP2
Biological: nivolumab

First Posted Date: 2020-04-07

Last Posted Date: 2024-08-09

Lead Sponsor: Replimune Inc.

Target Recruit Count: 36

Registration Number: NCT04336241

Locations: 🇪🇸
Hospital Clinico de Valencia, Valencia, Spain
🇬🇧
The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Merseyside, United Kingdom
🇪🇸
Hospital Universitario d'Hebron, Barcelona, Spain

and more 4 locations

Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer

Phase 2

Active, not recruiting

Conditions: Advanced Cutaneous Squamous Cell Carcinoma
Metastatic Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma

Interventions: Drug: Cemiplimab
Biological: RP1

First Posted Date: 2019-08-08

Last Posted Date: 2024-04-02

Lead Sponsor: Replimune Inc.

Target Recruit Count: 231

Registration Number: NCT04050436

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇫🇷
CHU Besancon - Hopital Jean Minjoz, Besancon, France
🇩🇪
Universitatsklinikum Heidelberg: National Centre for Tumour Diseases (NCT), Heidelberg, Germany

and more 53 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy